Concord Biotech’s Board of Directors will convene on November 13, 2025, to review and approve the standalone and consolidated unaudited financial results for the second quarter (Q2: Jul-Sep) and first half (H1) of the fiscal year ended September 30, 2025. The meeting will also involve reviewing the auditors’ report and considering other business matters.
Board Meeting for Financial Results
A meeting of the Board of Directors of Concord Biotech is scheduled for November 13, 2025. The primary agenda is to consider and approve the Standalone and Consolidated Unaudited Financial Results. These results are for the second quarter (Q2: Jul-Sep) and the half-year (H1), both ending September 30, 2025.
Trading Window Closure
In line with company policy, the trading window for dealing in the company’s securities remains closed. This closure aligns with the earlier communication issued on September 25, 2025, regarding the ‘Closure of Trading Window.’ The window will remain closed until 48 hours after the declaration of the financial results for Q2 and H1 ended September 30, 2025.
Source: BSE
